Ovid Therapeutics
OVID Healthcare Biotechnology
Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024. In the quarter to June 2026, revenue grew 463.9%, EPS fell 33.3%, free cash flow fell 268.5% and total debt fell 11.7%, each against the same quarter a year earlier.
Follow OVID
Ovid Therapeutics (OVID) EV/Sales
As of 16 October 2026, Ovid Therapeutics (OVID) trades at a EV/Sales of 40.6×. Over the past ten years it has ranged from −55.5× (June 2024) to 1,002× (September 2023); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.6× | (81.43%) |
| FY2024 | 46.4× | (87.29%) |
| FY2023 | 365× | 324,440.50% |
| FY2022 | 0.1× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 54.1× | 527.64% |
| Dec 2025 | 8.6× | (28.03%) |
| Sep 2025 | 12.0× | — |
| Jun 2025 | −0.3× | — |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 2.6× |
| PRTA Prothena Corporation plc compare | 2.7× |
| OVID Ovid Therapeutics | 40.6× |
| PROK ProKidney Corp. compare | 81.8× |
| OCS Oculis Holding AG compare | 109× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)